Who can participate?

Participants must be:

- Diagnosed with SMA
- Male between 18 and 50 years of age
- Currently taking risdiplam **OR** previously took risdiplam
- Actively trying to conceive **OR** conceived in the past (during or after taking risdiplam)

Female partners/surrogates/gestational carriers also have the option to participate in this study.

To learn more, visit

MARLINStudy.com

To participate, scan the QR code below to provide your contact information so a member of the study team can follow up with you.

Call us
1-855-662-7546
(1-855-6MARLIN)

Monday – Friday 8am-5pm ET

MARLIN

Thank you for considering participation in the MARLIN Study!

A Study to Describe the Fertility Journey of Risdiplam-Treated Adult Male Individuals with Spinal Muscular Atrophy

MARLIN

STUDY INFORMATION BROCHURE

Genentech
A Member of the Roche Group

What is the MARLIN Study?

The MARLIN Study is an observational study aimed at understanding the fertility experiences of men diagnosed with spinal muscular atrophy (SMA) who are actively attempting to conceive or have conceived in the past and are taking or have taken risdiplam.

Approximately 30 male participants from the U.S. will join this study. Female partners/surrogates/gestational carriers also have the option to take part in this study.

Why participate?

Should you qualify and choose to participate, you will be asked to provide information that may help doctors and researchers better understand the overall impact of risdiplam, an FDA-approved medication for SMA. Taking part in this study is your choice. You can leave the study at any time.

A Study to Describe the Fertility Journey of Risdiplam-Treated Adult Male Individuals with Spinal Muscular Atrophy

What will participants be required to do?

The study consists of questionnaires only. It does not include any treatments or procedures such as laboratory tests or doctor visits.

Participants will be asked to complete a questionnaire upon enrollment. For some participants, this will be the end of the study. Other participants will be asked to complete a follow-up questionnaire annually for up to 4 years. Each questionnaire will be completed on a smartphone application (i.e., app) and will take approximately 20-45 minutes to complete.

Female partners/surrogates/gestational carriers who decide to participate will be asked to complete similar questionnaires. Male participants can take part in this study, whether or not their female partner/surrogate/gestational carrier decides to participate.

MARLIN

What is an Informed Consent Form (ICF)?

The Informed Consent Form describes the study and how data may be shared for study purposes. By signing the consent form, participants are agreeing to take part in the study. Please read the Informed Consent Form carefully.

Will my privacy be protected?

The study team will respect the privacy of all participants who take part in the study. All personal and medical information will be kept strictly confidential. For further information about privacy, please see the Informed Consent Form.